menu search

RDY / COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar

COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar
COYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302. Read More
Posted: Mar 21 2023, 13:00
Author Name: Zacks Investment Research
Views: 111556

RDY News  

Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term

By Zacks Investment Research
November 2, 2023

Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Pre more_horizontal

Dr. Reddy's (RDY) Q2 Earnings and Revenues Beat Estimates

By Zacks Investment Research
October 30, 2023

Dr. Reddy's (RDY) Q2 Earnings and Revenues Beat Estimates

Dr. Reddy's (RDY) reports better-than-expected fiscal second-quarter 2024 results where both earnings and revenues beat estimates, driven by growth in more_horizontal

All You Need to Know About Doctor Reddy's (RDY) Rating Upgrade to Strong Buy

By Zacks Investment Research
October 26, 2023

All You Need to Know About Doctor Reddy's (RDY) Rating Upgrade to Strong Buy

Doctor Reddy's (RDY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong more_horizontal

3 Reasons Growth Investors Will Love Doctor Reddy's (RDY)

By Zacks Investment Research
October 4, 2023

3 Reasons Growth Investors Will Love Doctor Reddy's (RDY)

Doctor Reddy's (RDY) could produce exceptional returns because of its solid growth attributes. more_horizontal

Doctor Reddy's (RDY) Loses -6.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

By Zacks Investment Research
September 26, 2023

Doctor Reddy's (RDY) Loses -6.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Doctor Reddy's (RDY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement am more_horizontal

Here is Why Growth Investors Should Buy Doctor Reddy's (RDY) Now

By Zacks Investment Research
September 18, 2023

Here is Why Growth Investors Should Buy Doctor Reddy's (RDY) Now

Doctor Reddy's (RDY) could produce exceptional returns because of its solid growth attributes. more_horizontal

Looking for a Growth Stock? 3 Reasons Why Doctor Reddy's (RDY) is a Solid Choice

By Zacks Investment Research
August 31, 2023

Looking for a Growth Stock? 3 Reasons Why Doctor Reddy's (RDY) is a Solid Choice

Doctor Reddy's (RDY) could produce exceptional returns because of its solid growth attributes. more_horizontal

Here's Why You Should Add Dr. Reddy's (RDY) to Your Portfolio

By Zacks Investment Research
August 18, 2023

Here's Why You Should Add Dr. Reddy's (RDY) to Your Portfolio

Dr. Reddy's (RDY) continues to enjoy a strong foothold in the global generics market due to its deep generic drugs pipeline. The company is also looki more_horizontal


Search within

Pages Search Results: